|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.63/1.87
|
企业价值
1.74B
|
资产负债 |
每股账面净值
3.29
|
现金流量 |
现金流量率
0.09
|
损益表 |
收益
398.20M
|
每股收益
2.95
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 08:38 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |